Wordt geladen...
Response and Resistance to BCR-ABL1-Targeted Therapies
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for successful application of molecularly targeted cancer therapy. The development of the tyrosine kinase inhibitor (TKI) imatinib allows patients with CML to experience near-nor...
Bewaard in:
| Gepubliceerd in: | Cancer Cell |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7722523/ https://ncbi.nlm.nih.gov/pubmed/32289275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2020.03.006 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|